Search BSX
BOSTON SCIENTIFIC CORP
NYSE · CIK 885725
Last close42.6
Daily change-0.63 (-1.46%)
10 Years gain+81.28%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BSX · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
62.1Momentum
65.3Acceleration
65.3Confidence
86.0Annual Revenue19
Quarterly Revenue67
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.8 / 25
Quality17.5 / 25
Capital Efficiency11.8 / 20
Balance Sheet8.9 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.5817 percentage points.
Operating leverageOperating margin improved by 3.0505 percentage points.
Share count reductionDiluted share count declined 1.2256%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM23.28%OK
Revenue CAGR 3Y16.54%OK
Gross Margin69.46%OK
Operating Margin19.96%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC14.39%OK
Incremental Operating Margin 3Y32.84%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.23%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $20.07B | $13.85B | $3.61B | $4.53B | $3.66B | 69.01% | 18% | 18.22% | 13.51% | 1.49B |
| 2025 FY Dec 31, 2024 | $16.75B | $11.49B | $2.60B | $3.44B | $2.65B | 68.61% | 15.54% | 15.79% | 10.01% | 1.49B |
| 2025 FY Dec 31, 2023 | $14.24B | $9.90B | $2.34B | $2.50B | $1.79B | 69.49% | 16.45% | 12.58% | 10.55% | 1.46B |
| 2024 FY Dec 31, 2022 | $12.68B | $8.73B | $1.65B | $1.53B | $938.00M | 68.81% | 13% | 7.4% | 6.78% | 1.44B |
| 2023 FY Dec 31, 2021 | $11.89B | $8.18B | $1.20B | $1.87B | $1.32B | 68.78% | 10.09% | 11.07% | 8.11% | 1.43B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $20.77B | sum latest 4 fiscal quarters Revenue | OK | 0000885725-26-000053, 0000885725-25-000050 |
| Revenue Growth TTM | 23.28% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000885725-26-000053, 0000885725-25-000050 |
| Revenue CAGR 3Y | 16.54% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000885725-26-000010 |
| Revenue CAGR 5Y | 15.16% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000885725-26-000010 |
| Gross Profit CAGR 3Y | 16.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000885725-26-000010 |
| Operating Income Growth | 45.52% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000885725-26-000053, 0000885725-25-000050 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 69.46% | Gross Profit / Revenue | OK | 0000885725-26-000053, 0000885725-25-000050 |
| Operating Margin | 19.96% | Operating Income / Revenue | OK | 0000885725-26-000053, 0000885725-25-000050 |
| ROIC | 14.39% | NOPAT / Average Invested Capital | OK | 0000885725-26-000053, 0000885725-25-000050 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000885725-26-000053 |
| Interest Coverage | 11.42x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1.24x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.32x | (Cash + Short-term Investments) / Total Debt | OK | 0000885725-26-000053 |